Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B

10 Jun 2026
www.fiercebiotech.com
License out/in
Novartis has a track record of returning to its preferred molecular glue partners.
Novartis has stuck on a second deal with Orionis Biosciences, this time handing $40 million upfront to the molecular glue biotech to work on “challenging therapeutic targets across multiple disease areas.”
Novartis2020, the companies signed a fourOrionis Biosciencesver “historically elusive targets” for various unnamed diseases. While the financial details of that deal weren’t disclosed at the time, this morning’s agreement shows that Novartis is serious about the relationship.
The Swiss pharma is stumping up $40 million for this latest “multi-year collaboration” to make use of Orionis’ Allo-Glue platform and its AI-driven discovery engine to “accelerate target and ligase profiling and molecular glue optimiNovartis according to a June 10 release.
Molecular glues are small molecules used to stabilize the interaction between two proteins that don’t typically interact. Orionis’ Allo-Glue platform uses an array of chemical biology tech to design and optimize small molecules that promote or induce interactions of proteins in living cells.
Waltham, Massachusetts-headquartered Orionis is also eligible for up to $1.4 billion in research, development and commercial milestone payments from today's deal, as well as tiered royalties should any drugs make it to market.
Novartis has a track record of returnOrionisits preferred molecular glue partners. The Basel-based pharma has spent $270 million in upfront cash across two deals with Monte Rosa Therapeutics.
Novartis’ head of discovery John Tallarico said in the release that Orionis’ platform “offers an opportunity to rapidly uncover and design molecular glue mechanisms, eMonte Rosa Therapeuticse horizon of targetable biology for future therapies.”
Novartisr glue tech—including targeted protein degraders—has continued to gain Big Pharma attention. Last year saw Eli Lilly hand Magnet Biomedicine $40 million in upfront, near-term payments and an equity investment, while Gilead Sciences committed $85 million in upfront and potential option exercise payments for a chance to license a CDK2-directed asset from Kymera Therapeutics.
Orionis was co-founded by former Forma Therapeutics Vice President Nikolai KleyBig Pharmaes as its CEO, and VIB-GheEliULillysity pMagnet Biomedicinenier, who now serves as scientific advisor. In today's release, Kley said thGilead Sciencesroud to renew and expand our collaboration with Novartis.”CDK2-directedKymera Therapeutics
Orionis such a partner continue tForma Therapeuticsth us is a strong validation of the value of our molecular glue platform and the progress we have achieved toward rational and scalable discovery of this emerging drug class,” Kley added.Novartis
Orionis has already taken drugs into the clinic in the form of the solid tumor-focused ORB-011, which binds to and activates cDC1 dendritic cells, and ORB-021, which is engineered to direct cytokine activation to specific immune cells.
Novartis isn’t the only Swiss pharma to build a relationship with Osolid tumort year, RORB-011Genentech signed its second paccDC1th the biotech, with OORB-021receiving $105 million upfront to work on small-molecule monovalent glue medicines aimed at “novel and challenging targets” in oncology.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!